Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28590805 | 0.77 | KDM4E (0.46) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL8649103 | 0.75 | ELANE (0.51) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL1664069 | 0.75 | MEN1 (0.46) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL20944983 | 0.74 | ELANE (0.50) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL8102665 | 0.73 | KDM4E (0.50) | KDM4ESMN1; SMN2GAAALDH1A1 | |
| SCHEMBL28625554 | 0.73 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL9609770 | 0.73 | KDM4E (0.50) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL7095748 | 0.72 | KDM4E (0.53) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL22114505 | 0.72 | KDM4E (0.49) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 | |
| SCHEMBL29255151 | 0.72 | KDM4E (0.49) | KDM4ESMN1; SMN2GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| CN-106456602-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2020-11-24 | — | — | CN | disclosed |
| EP-3122353-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| EP-3122353-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | KDM4E 814/4885SMN1; SMN2 2394/4885GAA 4009/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | KDM4E 814/4885SMN1; SMN2 2394/4885GAA 4009/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | KDM4E 814/4885SMN1; SMN2 2394/4885GAA 4009/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | KDM4E 814/4885SMN1; SMN2 2394/4885GAA 4009/4885 |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | KDM4E 814/4885SMN1; SMN2 2394/4885GAA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.